# Aflac Inc: financial statements, quarterly

AFL · NYSE · CIK 4977 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/afl.md) · [Financials](/companies/afl/financials.md) · [Filings](/companies/afl/filings.md) · [Insiders](/companies/afl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/afl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,950](/filings/0000004977-24-000167.md) | [3,777](/filings/0000004977-24-000053.md) | [5,436](/filings/0000004977-25-000075.md) | [5,138](/filings/0000004977-25-000132.md) | [2,949](/filings/0001628280-25-049279.md) | [5,403 d](/filings/0001628280-26-011402.md) | [3,398](/filings/0001628280-26-030923.md) | [4,160](/filings/0001628280-26-054618.md) | [4,740](/filings/0001628280-25-049279.md) | [4,866 d](/filings/0001628280-26-011402.md) | [4,346](/filings/0001628280-26-030923.md) | [4,117](/filings/0001628280-26-054618.md) |
| Selling, general and administrative | $m | [785](/filings/0000004977-24-000167.md) | [875 d](/filings/0001628280-26-011402.md) | [739](/filings/0000004977-25-000075.md) | [694](/filings/0000004977-25-000132.md) | [747](/filings/0001628280-25-049279.md) | [835 d](/filings/0001628280-26-011402.md) | [802](/filings/0001628280-26-030923.md) | [804](/filings/0001628280-26-054618.md) | [781](/filings/0001628280-25-049279.md) | [866 d](/filings/0001628280-26-011402.md) | [771](/filings/0001628280-26-030923.md) | [749](/filings/0001628280-26-054618.md) |
| Operating income | $m | [1,298](/filings/0000004977-23-000177.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [49.0](/filings/0000004977-23-000177.md) | [47.0 d](/filings/0000004977-24-000053.md) | [47.0](/filings/0000004977-24-000086.md) | [50.0](/filings/0000004977-24-000140.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [236](/filings/0000004977-24-000167.md) | [21.0](/filings/0000004977-24-000053.md) | [291](/filings/0000004977-25-000075.md) | [264](/filings/0000004977-25-000132.md) | [185](/filings/0001628280-25-049279.md) | [233 d](/filings/0001628280-26-011402.md) | [116](/filings/0001628280-26-030923.md) | [223](/filings/0001628280-26-054618.md) | [355](/filings/0001628280-25-049279.md) | [193 d](/filings/0001628280-26-011402.md) | [206](/filings/0001628280-26-030923.md) | [170](/filings/0001628280-26-054618.md) |
| Net income | $m | [1,569](/filings/0000004977-24-000167.md) | [268](/filings/0000004977-24-000053.md) | [1,879](/filings/0001628280-25-049279.md) | [1,755](/filings/0001628280-25-049279.md) | [(93.0)](/filings/0001628280-25-049279.md) | [1,902 d](/filings/0001628280-26-011402.md) | [29.0](/filings/0001628280-26-054618.md) | [599](/filings/0001628280-26-054618.md) | [1,639](/filings/0001628280-25-049279.md) | [1,379 d](/filings/0001628280-26-011402.md) | [1,019](/filings/0001628280-26-054618.md) | [825](/filings/0001628280-26-054618.md) |
| Diluted EPS | $ per share | [2.64](/filings/0000004977-24-000167.md) | [0.46](/filings/0000004977-24-000053.md) | [3.25](/filings/0000004977-25-000075.md) | [3.10](/filings/0000004977-25-000132.md) | [(0.17)](/filings/0001628280-25-049279.md) | not reported | [0.05](/filings/0001628280-26-030923.md) | [1.11](/filings/0001628280-26-054618.md) | [3.08](/filings/0001628280-25-049279.md) | not reported | [1.98](/filings/0001628280-26-030923.md) | [1.63](/filings/0001628280-26-054618.md) |
| Basic EPS | $ per share | [2.65](/filings/0000004977-24-000167.md) | [0.46](/filings/0000004977-24-000053.md) | [3.27](/filings/0000004977-25-000075.md) | [3.11](/filings/0000004977-25-000132.md) | [(0.17)](/filings/0001628280-25-049279.md) | not reported | [0.05](/filings/0001628280-26-030923.md) | [1.12](/filings/0001628280-26-054618.md) | [3.09](/filings/0001628280-25-049279.md) | not reported | [1.99](/filings/0001628280-26-030923.md) | [1.64](/filings/0001628280-26-054618.md) |

- Revenue: us-gaap:Revenues
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [5.5](/filings/0000004977-23-000177.md) | [4.3](/filings/0000004977-25-000047.md) | [5.1](/filings/0000004977-24-000086.md) | [6.1](/filings/0000004977-24-000140.md) | [5.6](/filings/0000004977-24-000167.md) | [6.2](/filings/0001628280-26-011402.md) | [5.2](/filings/0000004977-25-000075.md) | [7.0](/filings/0000004977-25-000132.md) | [6.8](/filings/0001628280-25-049279.md) | [6.2](/filings/0001628280-26-054618.md) | [5.7](/filings/0001628280-26-030923.md) | [6.1](/filings/0001628280-26-054618.md) |
| Total assets | $bn | [125](/filings/0000004977-23-000177.md) | [127](/filings/0000004977-25-000047.md) | [125](/filings/0000004977-24-000086.md) | [120](/filings/0000004977-24-000140.md) | [128](/filings/0000004977-24-000167.md) | [118](/filings/0001628280-26-011402.md) | [120](/filings/0000004977-25-000075.md) | [125](/filings/0000004977-25-000132.md) | [122](/filings/0001628280-25-049279.md) | [116](/filings/0001628280-26-054618.md) | [116](/filings/0001628280-26-030923.md) | [116](/filings/0001628280-26-054618.md) |
| Total liabilities | $bn | [102](/filings/0000004977-23-000177.md) | [105](/filings/0000004977-25-000047.md) | [101](/filings/0000004977-24-000086.md) | [94.1](/filings/0000004977-24-000140.md) | [104](/filings/0000004977-24-000167.md) | [91.5](/filings/0001628280-26-011402.md) | [93.9](/filings/0000004977-25-000075.md) | [97.5](/filings/0000004977-25-000132.md) | [93.6](/filings/0001628280-25-049279.md) | [87.0](/filings/0001628280-26-054618.md) | [86.3](/filings/0001628280-26-030923.md) | [85.6](/filings/0001628280-26-054618.md) |
| Shareholders' equity | $bn | [22.7](/filings/0000004977-24-000167.md) | [22.0](/filings/0001628280-26-011402.md) | [23.5](/filings/0001628280-25-049279.md) | [26.0](/filings/0001628280-25-049279.md) | [24.8](/filings/0001628280-25-049279.md) | [26.1](/filings/0001628280-26-054618.md) | [26.3](/filings/0001628280-26-054618.md) | [27.2](/filings/0001628280-26-054618.md) | [28.7](/filings/0001628280-25-049279.md) | [29.5](/filings/0001628280-26-054618.md) | [30.0](/filings/0001628280-26-054618.md) | [30.3](/filings/0001628280-26-054618.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,276 d](/filings/0000004977-24-000167.md) | [582 d](/filings/0001628280-26-011402.md) | [849](/filings/0000004977-25-000075.md) | [255 d](/filings/0000004977-25-000132.md) | [1,270 d](/filings/0001628280-25-049279.md) | [333 d](/filings/0001628280-26-011402.md) | [589](/filings/0001628280-26-030923.md) | [399 d](/filings/0001628280-26-054618.md) | [1,252 d](/filings/0001628280-25-049279.md) | [315 d](/filings/0001628280-26-011402.md) | [968](/filings/0001628280-26-030923.md) | [112 d](/filings/0001628280-26-054618.md) |
| Dividends paid | $m | [239 d](/filings/0000004977-24-000167.md) | [236 d](/filings/0001628280-26-011402.md) | [278](/filings/0000004977-25-000075.md) | [272 d](/filings/0000004977-25-000132.md) | [270 d](/filings/0001628280-25-049279.md) | [267 d](/filings/0001628280-26-011402.md) | [306](/filings/0001628280-26-030923.md) | [301 d](/filings/0001628280-26-054618.md) | [299 d](/filings/0001628280-25-049279.md) | [292 d](/filings/0001628280-26-011402.md) | [304](/filings/0001628280-26-030923.md) | [299 d](/filings/0001628280-26-054618.md) |
| Share repurchases | $m | [700 d](/filings/0000004977-24-000167.md) | [701 d](/filings/0001628280-26-011402.md) | [750](/filings/0000004977-25-000075.md) | [800 d](/filings/0000004977-25-000132.md) | [500 d](/filings/0001628280-25-049279.md) | [750 d](/filings/0001628280-26-011402.md) | [900](/filings/0001628280-26-030923.md) | [829 d](/filings/0001628280-26-054618.md) | [1,000 d](/filings/0001628280-25-049279.md) | [801 d](/filings/0001628280-26-011402.md) | [1,000](/filings/0001628280-26-030923.md) | [984 d](/filings/0001628280-26-054618.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [632](/filings/0000004977-23-000177.md) | [614](/filings/0000004977-24-000086.md) | [603](/filings/0000004977-24-000140.md) | [594](/filings/0000004977-24-000167.md) | [577](/filings/0000004977-25-000075.md) | [567](/filings/0000004977-25-000132.md) | [560](/filings/0001628280-25-049279.md) | [547](/filings/0001628280-26-030923.md) | [538](/filings/0001628280-26-054618.md) | [532](/filings/0001628280-25-049279.md) | [515](/filings/0001628280-26-030923.md) | [506](/filings/0001628280-26-054618.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 501,343,298 at 2026-07-28, from the cover of the [10-Q filed 2026-08-07](/filings/0001628280-26-054618.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.